Graft Polymer PLC Regulatory News (GPL)

12 August 2024

Graft Polymer (UK) Plc

("Graft Polymer" or the "Company")

Director resignation

Graft Polymer (UK) Plc (LON: GPL), an innovative biopolymer drug delivery systems development company, announces the resignation, with immediate effect, of Yifat Steuer from its board of directors and from the role of Chief Financial Officer.

Orana Corporate LLP will continue to provide support in relation to the Company's financial function whilst the Company proceeds to select a new CFO.

Nicholas Nelson, Chairman, commented:

"Yifat departs us with our sincere thanks for all she has done during the transitionary period since I became Chairman. She has provided us with invaluable guidance and professionalism.

"New board appointments are planned to steer the Company as it pursues its mission to innovate in drug delivery solutions. "

Enquiries:

Graft Polymer (UK) PlcAnthony Tennyson, CEO and Executive DirectorEmail: anthonytennyson@graftpolymer.co.uk

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales) 

+44 (0) 20 3328 5656 

About Graft Polymer (UK) Plc

Graft Polymer plc ("Graft Polymer") (LON: GPL) is an innovative biopolymer drug delivery systems development company dedicated to enabling biopharmaceutical companies to enhance the effectiveness of their therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying drug delivery system (SNEDDS), represents a cutting-edge solution in drug delivery technology. By integrating active pharmaceutical ingredients (APIs) into our novel, patented delivery systems, we enable clients to improve the pharmacokinetics, bioavailability, and stability of their therapeutics.

For more information, please visit www.graftpolymer.co.uk.